All In Biotech

Drug Trial Radar · NCT05690841

FocaL Mass Drug Administration for Vivax Malaria Elimination

FocaL Mass Drug Administration for Vivax Malaria Elimination (FLAME): a Pragmatic Cluster Randomized Controlled Trial in Peru

Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 7,530 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

7,530

Planned (sponsor's estimate)

Start

Oct 14, 2024

Primary completion

May 1, 2027

Study completion May 1, 2027

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Universidad Peruana Cayetano Heredia; PATH; Stanford University; Oxford University Clinical Research Unit Indonesia; Menzies School of Health Research; National Institute of Allergy and Infectious Diseases (NIAID); GlaxoSmithKline; Medicines for Malaria Venture
First posted
Jan 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

FLAME is an open-label cluster-randomized controlled trial that aims to determine the effectiveness of focal mass drug administration (fMDA) to reduce the incidence of Plasmodium vivax malaria in the Loreto Department in Peru. Standard interventions, including symptomatic and asymptomatic screening for malaria infections, provision of insecticide-treated bednets, and environmental transmission monitoring, will be compared to clusters of villages randomized to receive anti-malarial drugs.

Conditions

  • Plasmodium Vivax Malaria
  • Malaria

Interventions

  • Focal Mass Drug Administration (fMDA)Drug

    Administration of focal mass drug administration for high-risk individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household). Intervention to be administered two times, two months apart each cycle, for 3 cycles spaced apart by regular intervals. Each year will include 2 rounds of fMDA. Round 1) Chloroquine (CQ)+ Tafenoquine (TQ) for \>= 16y (CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg CQ, TQ 300 mg on Day 1); CQ+ Primaquine (PQ) for \<16y (CQ: age-based dosing, PQ age-based dosing); CQ+PQ for G6PD intermediate individuals \>=6mo and \<16y ((CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg, PQ age-based dosing). Round 2) single dose CQ+TQ for \>= 16y (CQ: Day1 600 mg, TQ 300 mg on Day 1); single dose CQ+PQ for \<16y (CQ: age-based dosing, PQ age-based dosing); single dose CQ+PQ for G6PD intermediate individuals \>=6mo and \<16y ((CQ: Day1 600 mg, PQ age-based dosing).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative Incidence of Plasmodium vivax infectionsTime frame: From enrollment through study completion, over 36-month follow-up study period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asociación Civil Selva Amazónica

    Iquitos, Peru · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.